Recently, we found that a high expression of CaN was correlated with a poor prognosis regarding the outcome of endocrine therapy in patients with ERα-positive breast cancer [132], which indicates that the selective inhibition of CaN could be effective to treat such cancers. This evidence concerns the gene ESR1 and cancer.